SCHEMBL7927426

SCHEMBL7927426

C[C@H](N)C(=O)N[C@@H](CCC(=O)O)C(N)=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD1 Q9Y239 1/20 0.59
GABRP O00591 2/20 0.48
GABRD O14764 2/20 0.48
GABRA1 P14867 2/20 0.48
GABRB1 P18505 2/20 0.48
GABRG2 P18507 2/20 0.48
GABRB3 P28472 2/20 0.48
GABRA5 P31644 2/20 0.48
GABRA3 P34903 2/20 0.48
GABRA2 P47869 2/20 0.48
GABRB2 P47870 2/20 0.48
GABRA4 P48169 2/20 0.48
GABRE P78334 2/20 0.48
GABRA6 Q16445 2/20 0.48
GABRG1 Q8N1C3 2/20 0.48
GABRG3 Q99928 2/20 0.48
GABRQ Q9UN88 2/20 0.48
DPP4 P27487 2/20 0.46
DPP8 Q6V1X1 1/20 0.46
DPP9 Q86TI2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11103615 1.00 NOD1 (0.59) NOD1GABRPGABRDGABRA1GABRB1
SCHEMBL27892995 1.00 NOD1 (0.59) NOD1GABRPGABRDGABRA1GABRB1
SCHEMBL4217551 1.00 NOD1 (0.59) NOD1GABRPGABRDGABRA1GABRB1
Hydrochloric Acid SCHEMBL7349143 0.98 NOD1 (0.58) NOD1GABRPGABRDGABRA1GABRB1
SCHEMBL10888261 0.94 NOD1 (0.54) NOD1GABRPGABRDGABRA1GABRB1
Trifluoroacetic Acid SCHEMBL25386515 0.91 NOD1 (0.52) NOD1GABRPGABRDGABRA1GABRB1
Trifluoroacetic Acid SCHEMBL11191547 0.91 NOD1 (0.52) NOD1GABRPGABRDGABRA1GABRB1
SCHEMBL17888187 0.88 NOD1 (0.49) NOD1GABRPGABRDGABRA1GABRB1
SCHEMBL1270356 0.87 FOLH1 (0.60) NOD1GABRPGABRDGABRA1GABRB1
SCHEMBL2490631 0.87 FOLH1 (0.60) NOD1GABRPGABRDGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6063613-A MUTANT STAPHYLOCOCCUS AUREUS CAUSED BY INSERTION OF TRANSPOSON TN551; CAUSES INCORPORATION OF PARTIALLY BLOCKED MUROPEPTIDE PRECURSORS INTO CELL WALL; FOR SCREENING DRUGS THAT CAN REVERSE, INHIBIT OR REDUCE BACTERIAL RESISTANCE THE ROCKEFELLER UNIVERSITY (US) 2000-05-16 US claimed
WO-1995016039-A1 AUXILIARY GENES AND PROTEINS OF METHICILLIN RESISTANT BACTERIA AND ANTAGONISTS THEREOF THE ROCKEFELLER UNIVERSITY (US) 1995-06-15 WO claimed
CN-119604618-A Epstein-Barr virus vaccine 巴法里安诺迪克有限公司 2025-03-11 CN disclosed
US-11925643-B2 Toll-like receptor 4 (TLR4) inhibitors and use thereof MOR RESEARCH APPLICATIONS LTD. (IL) 2024-03-12 US disclosed
CN-116396940-A Hematopoietic stem progenitor cells, preparation method and application thereof 北京干细胞与再生医学研究院 2023-07-07 CN disclosed
CN-108884439-A For cultivating method, culture medium and the product of embryo 阿德莱德大学 2018-11-23 CN disclosed
US-8278090-B1 Heterotrophic cultivation of hydrocarbon-producing microalgae SOLAZYME, INC. (US) 2012-10-02 US disclosed
US-6251647-B1 NUCLEOTIDE AND AMINO ACID SEQUENCES; DRUG SCREENING OF BACTERICIDES FOR STAPHYLOCOCCUS INFECTIONS THE ROCKEFELLER UNIVERSITY 2001-06-26 US disclosed
US-6136587-A ANTIBIOTIC RESISTANT STAPHYLOCOCCUS STRAIN HAVING A MUTATION IN A GENE WHICH LEADS TO AMPLIFIED SENSITIVITY TO ANTIBIOTICS; FOR THE TREATMENT OF MICROORGANISM INFECTION THE ROCKEFELLER UNIVERSITY (US) 2000-10-24 US disclosed
US-6063613-A MUTANT STAPHYLOCOCCUS AUREUS CAUSED BY INSERTION OF TRANSPOSON TN551; CAUSES INCORPORATION OF PARTIALLY BLOCKED MUROPEPTIDE PRECURSORS INTO CELL WALL; FOR SCREENING DRUGS THAT CAN REVERSE, INHIBIT OR REDUCE BACTERIAL RESISTANCE THE ROCKEFELLER UNIVERSITY (US) 2000-05-16 US disclosed
US-6013507-A NUCLEIC ACID SEQUENCES WHICH CODE FOR A PROTEIN ASSOCIATED WITH ANTIBIOTIC RESISTANCE IN STAPHYLOCUCCUS; FOR THE DETECTION OF COMPOUNDS THAT CAN REVERSE ANTIBIOTIC RESISTANCE THE ROCKEFELLER UNIVERSITY (US) 2000-01-11 US disclosed
US-6008333-A Preparation of glucosaminyl muramic acid derivatives ENDOREX CORPORATION (US) 1999-12-28 US disclosed
EP-0873345-A1 PREPARATION OF GLUCOSAMINYL MURAMIC ACID DERIVATIVES Endorex Corporation (US) 1998-10-28 EP disclosed
US-5750665-A Preparation of glucosaminyl muramic acid derivatives ENDOREX CORPORATION 1998-05-12 US disclosed
WO-1997012894-A1 PREPARATION OF GLUCOSAMINYL MURAMIC ACID DERIVATIVES ENDOREX CORPORATION (US) 1997-04-10 WO disclosed
WO-1995016039-A1 AUXILIARY GENES AND PROTEINS OF METHICILLIN RESISTANT BACTERIA AND ANTAGONISTS THEREOF THE ROCKEFELLER UNIVERSITY (US) 1995-06-15 WO disclosed
EP-0346460-B1 PURINE DERIVATIVES HAVING PHARMACOLOGICAL ACTION CO PHARMA CORPORATION (IT) 1993-03-10 EP disclosed
US-5110798-A Immunomodulators for bone marrow transplants CO PHARMA CORPORATION S.R.L. (IT) 1992-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11925643-B2 Toll-like receptor 4 (TLR4) inhibitors and use thereof TLR4, TLR1, TLR3 NOD1 9/4885GABRP 2241/4885GABRD 3308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.